NCT07295275Recruiting
Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
Safety and Efficacy of Trans-arterial Versus Trans-portal ICG Fluorescence-Guided Laparoscopic Liver Watershed Resection: A Multicenter, Ambispective Cohort Study
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC). The study aims to compare the outcomes of the trans-arterial ICG staining approach versus the conventional trans-portal (portal vein) ICG staining approach.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 7 Dec 2025
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- West China Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07295275
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Mar 2026 to the primary completion date, 1 Jan 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant other active malignancies.
- Preoperative anti-tumor therapy (TACE, ablation, radiotherapy, systemic therapy) or history of prior hepatectomy.
- Conversion to open surgery.
- Unclear surgical records regarding ICG staining method.
Other illness
- Pathology confirms non-HCC components (e.g., cholangiocarcinoma, combined HCC-ICC) or metastatic liver cancer.
- Intraoperative ICG staining failure (e.g., diffuse staining, unclear boundaries) preventing fluorescence-guided resection.
Other
- Ruptured tumor.
- Missing data preventing primary endpoint assessment.
Who the study is looking for
- Age 18-80 years.
- Postoperative histopathological diagnosis of Hepatocellular Carcinoma (HCC).
- Underwent ICG fluorescence-guided laparoscopic anatomical liver resection.
- Child-Pugh Class A or B.
- ASA score I-III.
- ECOG Performance Status 0-2.
- No invasion of major vessels (main portal vein/first-order branches, main hepatic vein).
- No distant metastasis.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tsinghua Changgung Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
| Xuzhou Central Hospital Coordinator of this site? Confirm its status | Xuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.